
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· August 5, 2026 · 16 min read
By Ran Chen#Infectious Disease#FDA Approval#PDUFA Date

Deals· August 2, 2026 · 25 min read
Angelini Pharma's $4.1B Catalyst Acquisition: Rare Disease Deal Anatomy
By Ran Chen#M&A#Rare Disease#Orange Book

Manufacturing· August 1, 2026 · 20 min read
FDA Warning Letters by the Numbers (2026): CDER Drug Enforcement Surge

Deals· August 1, 2026 · 20 min read
Gilead's $5B Tubulis Buyout: Deal Anatomy & NaPi2b ADC Platform
By Ran Chen#M&A#ADC#FDA Approval

Pipeline· July 31, 2026 · 20 min read
mRNA Vaccines Pipeline by the Numbers (2026): 459 Clinical Trials
By Ran Chen#Clinical Trials#RNA Therapy#FDA Approval

Pricing & Access· July 31, 2026 · 22 min read
Radioligand Therapy Access Landscape: Pluvicto, Lutathera & ITM PDUFA
By Ran Chen#Market Access#FDA Approval#HCPCS Coding

Pipeline· July 30, 2026 · 19 min read
Companion Diagnostics (2026): FDA PMA Supplement Expansion & Device Landscape
By Ran Chen#Companion Diagnostic#FDA Approval#Oncology

Specialty· July 30, 2026 · 20 min read
Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics

Specialty· July 29, 2026 · 24 min read
Hereditary Angioedema Treatment Access Landscape (2026)

Pipeline· July 29, 2026 · 25 min read
RNA Therapeutics Clinical Trials by the Numbers (2026)
By Ran Chen#RNA Therapy#Clinical Trials#FDA Approval